Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Adults can and do get RSV, often experiencing it as a cold with runny nose, cough, sore throat, congestion, and fatigue that typically improves within one to two weeks. Severity varies widely: healthy adults usually recover at home, while adults over 60, those with asthma, COPD, heart failure, diabetes, or weakened immune systems face higher risk of bronchiolitis, pneumonia, worsening of chronic conditions, and hospitalization. Warning signs such as wheezing, shortness of breath, chest pain, high fever, or bluish lips call for prompt medical care, and several other factors influence how serious an infection becomes, so see below for the complete details you should consider.
Because RSV, flu, COVID-19, and common colds overlap heavily in early symptoms, guessing can delay treatment that works best when started quickly. Take a free, instant, online symptom check to clarify what your symptoms may point to, understand your personal risk level, and decide whether to rest at home, book a visit, or seek urgent care.
Last reviewed for medical accuracy: 09/23/2026
Respiratory syncytial virus (RSV) is often thought of as a childhood illness, but can adults get RSV? The short answer is yes. While many adults experience mild cold-like symptoms, RSV can lead to serious complications—especially in older adults and those with chronic health conditions. Below, we’ll cover what RSV is, how it affects adults, possible risks, and when to seek medical help.
RSV is a common respiratory virus that typically peaks in fall, winter, and early spring. It spreads through:
In infants and young children, RSV can cause bronchiolitis or pneumonia. In healthy adults, it often looks like a run-of-the-mill cold.
Yes. RSV doesn’t discriminate by age. In fact:
While any adult can catch RSV, certain groups face higher risks of complications:
When adults get RSV, symptoms often mirror a mild cold:
Most healthy adults recover in 1–2 weeks. However, RSV can sometimes lead to more severe issues.
Even in adults, RSV can progress beyond mild symptoms. Watch for:
Complications are more likely if you have an underlying health condition or weakened immunity.
Severity varies by individual:
According to credible public health sources, RSV in adults can result in thousands of hospitalizations each year.
If you suspect RSV, especially with worsening symptoms, a healthcare provider may:
Early diagnosis can help guide treatment and reduce the risk of serious complications.
There’s no specific antiviral treatment for RSV in most adults. Care focuses on symptom relief:
In severe cases, hospitalization may involve:
You can lower your risk of catching or spreading RSV by practicing good habits:
Most RSV cases in adults don’t require a doctor’s visit, but seek care if you experience:
For non-urgent concerns or to better understand your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you need to see a healthcare professional.
If you’re in a high-risk group or your symptoms worsen, share the following with your healthcare provider:
Clear communication ensures you get the right level of care.
Remember, if you have any life-threatening or serious symptoms, speak to a doctor right away. RSV can be unpredictable, and early medical evaluation is key for those at higher risk.
(References)
* Russell CD, Unger SA, Walton M, Schwarze J. The Human Immune Response to Respiratory Syncytial Virus Infection. Clin Microbiol Rev. 2017 Apr;30(2):481-502. doi: 10.1128/CMR.00090-16. PMID: 28179378; PMCID: PMC5355638.
* Pierangeli A, Scagnolari C, Antonelli G. Respiratory syncytial virus. Minerva Pediatr. 2018 Dec;70(6):553-565. doi: 10.23736/S0026-4946.18.05312-4. Epub 2018 Oct 18. PMID: 30334622.
* Wrotek A, Czajkowska M, Jackowska T. Seasonality of Respiratory Syncytial Virus Hospitalization. Adv Exp Med Biol. 2020;1279:93-100. doi: 10.1007/5584_2020_503. PMID: 32170670.
* Foley DA, Phuong LK, Englund JA. Respiratory syncytial virus immunisation overview. J Paediatr Child Health. 2020 Dec;56(12):1865-1867. doi: 10.1111/jpc.15232. Epub 2020 Oct 22. PMID: 33089944.
* Rajan A, Piedra FA, Aideyan L, McBride T, Robertson M, Johnson HL, Aloisio GM, Henke D, Coarfa C, Stossi F, Menon VK, Doddapaneni H, Muzny DM, Javornik Cregeen SJ, Hoffman KL, Petrosino J, Gibbs RA, Avadhanula V, Piedra PA. Multiple Respiratory Syncytial Virus (RSV) Strains Infecting HEp-2 and A549 Cells Reveal Cell Line-Dependent Differences in Resistance to RSV Infection. J Virol. 2022 Apr 13;96(7):e0190421. doi: 10.1128/jvi.01904-21. Epub 2022 Mar 14. PMID: 35285685; PMCID: PMC9006923.
* Bender W, Zhang Y, Corbett A, Chu C, Grier A, Wang L, Qiu X, McCall MN, Topham DJ, Walsh EE, Mariani TJ, Scheuermann R, Caserta MT, Anderson CS. Association of disease severity and genetic variation during primary Respiratory Syncytial Virus infections. BMC Med Genomics. 2024 Jun 19;17(1):165. doi: 10.1186/s12920-024-01930-7. Epub 2024 Jun 19. PMID: 38898440; PMCID: PMC11188216.
* Kristensen M, de Steenhuijsen Piters WAA, Wildenbeest J, van Houten MA, Zuurbier RP, Hasrat R, Arp K, Chu MLJN, Billard M, Heikkinen T, Cunningham S, Snape M, Drysdale SB, Thwaites RS, Martinon-Torres F, Pollard AJ, Openshaw PJM, Aerssen J, Binkowska J, Bont L, Bogaert D, REspiratory Syncytial virus Consortium in EUrope (RESCEU) investigators. The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children. Cell Rep Med. 2024 Dec 17;5(12):101836. doi: 10.1016/j.xcrm.2024.101836. Epub 2024 Dec 5. PMID: 39642873; PMCID: PMC11722103.
* Kirolos N, Mtaweh H, Datta RR, Farrar DS, Seaton C, Bone JN, Muttalib F, Kaziev CL, Fortini J, Mahant S, Campigotto A, Freire G, Yeung RSM, Rayment JH, Yang C, Srigley JA, Sadarangani M, Buchanan F, Morris SK, Gill PJ, READAPT-Kids Study Group Members. Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus. JAMA Netw Open. 2025 Apr 1;8(4):e254666. doi: 10.1001/jamanetworkopen.2025.4666. Epub 2025 Apr 1. PMID: 40214990; PMCID: PMC11992603.
* Zar HJ, Simões EAF, Madhi SA, Ramilo O, Senders SD, Shepard JS, Laoprasopwattana K, Piedrahita J, Novoa JM, Vargas SL, Dionne M, Jackowska T, Liu E, Ishihara Y, Ikeda K, Zhang Y, Railkar RA, Lutkiewicz J, Vora KA, Zang X, Maas BM, Lee AW, Guerra A, Sinha A, CLEVER (MK-1654-004) Study Group. Clesrovimab for Prevention of RSV Disease in Healthy Infants. N Engl J Med. 2025 Oct 2;393(13):1292-1303. doi: 10.1056/NEJMoa2502984. Epub 2025 Sep 17. PMID: 40961446.
* Di Maio VC, Scutari R, Mastropaolo M, Colagrossi L, Linardos G, Coltella L, Ranno S, Galeno E, Pisani M, Vittucci AC, Cristaldi S, Raponi M, Villani A, Russo C, Perno CF. Viral Burden of Respiratory Syncytial Virus and Viral Coinfections as Factors Regulating Paediatric Disease Severity. Viruses. 2025 Sep 11;17(9). doi: 10.3390/v17091236. Epub 2025 Sep 11. PMID: 41012664; PMCID: PMC12474089.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.